xchangeklion.blogg.se - Small protein scaffold better than antibody

Small molecule drugs (typically < 1000 Da) are the historical gold standard for drug development, typically targeting a small cleft in an enzyme or macromolecule and generally of limited immunogenicity. Pharmacological interventions can broadly be segregated into two categories with implications to their capabilities, development strategies, and regulatory hurdles. The University of Waikato.Molecular Therapeutic Modalities are Diverse in Structure and Capabilities Engineering and characterisation of anti-progesterone OBodies (Thesis thesis). "Engineering a targeted delivery platform using Centyrins". ^ Goldberg SD, Cardoso RM, Lin T, Spinka-Doms T, Klein D, Jacobs SA, et al."Monobodies as possible next-generation protein therapeutics - a perspective". ^ "Rapid identification and development of SARS-CoV-2 selective Optimers".

"Development of polyol-responsive antibody mimetics for single-step protein purification". ^ Suderman RJ, Rice DA, Gibson SD, Strick EJ, Chao DM (April 17, 2017)."Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain". "Engineered protein inhibitors of proteases". "Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid". ^ Wicke N, Bedford MR, Howarth M (August 2021)."A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties". ^ Grabulovski D, Kaspar M, Neri D (February 2007)."DARPins: a new generation of protein therapeutics". ^ Stumpp MT, Binz HK, Amstutz P (August 2008)."Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains". "Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities". "Structural basis of IL-23 antagonism by an Alphabody protein scaffold". ^ Desmet J, Verstraete K, Bloch Y, Lorent E, Wen Y, Devreese B, et al."Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD". ^ Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP (November 2008).

"Sensitive Affimer and antibody based impedimetric label-free assays for C-reactive protein".

^ Johnson A, Song Q, Ko Ferrigno P, Bueno PR, Davis JJ (Aug 7, 2012).

"Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein".

^ Ebersbach H, Fiedler E, Scheuermann T, et al.

"Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold". "Engineered protein scaffolds as next-generation antibody therapeutics". Highly stable fibronectin type III (FN3) domainĪ high affinity binding protein domain engineered to bind to Hen Egg-white Lysozyme Kunitz domains of various protease inhibitorsĬarbohydrate Binding Module 32-2 (from Clostridium perfringens NagH)įlexible nucleic acid based scaffold G-quadruplexįourteenth fibronectin type-III scaffold of Human Fibronectin (14Fn3) Antibody mimetics are being developed as therapeutic and diagnostic agents. Nucleic acids and small molecules are sometimes considered antibody mimetics as well, but not artificial antibodies, antibody fragments and fusion proteins composed from these.Ĭommon advantages over antibodies are better solubility, tissue penetration, stability towards heat and enzymes, and comparatively low production costs. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa. Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies.